In a nutshell This trial will evaluate a molecular test, EndoPredict®, in the treatment of breast cancer. The main outcome will be the adherence rate to EndoPredict® results. This trial is recruiting in South Carolina, USA. It is sponsored by Myriad Genetic Laboratories. The details Adjuvant chemotherapy (ACT) is...Read More
Current disease status-First occurrence of the cancer Posts on Medivizor
Evaluating long-term outcomes for stereotactic ablative body radiotherapy for early-stage non-small cell lung cancer.
In a nutshell This study wanted to find out if using stereotactic ablative body radiotherapy (SABR) improves survival in patients with early-stage non-small cell lung cancer (NSCLC). The study found that this treatment resulted in good long-term survival and had few side effects. Some background Stereotactic ablative body radiotherapy (SABR) is...Read More
In a nutshell This study evaluated the effectiveness of durvalumab (Imfinzi) combined with chemotherapy for patients with triple-negative breast cancer (TNBC). This study found that more patients treated with durvalumab had a complete disappearance of all signs of cancer (complete response) compared to placebo. Some...Read More
In a nutshell This article investigated the safety and effectiveness of androgen-deprivation therapy (ADT) combined with external beam radiation therapy (EBRT) for the treatment of locally advanced prostate cancer (LAPC). The authors concluded that ADT combined with EBRT is a safe and effective treatment option for these...Read More
In a nutshell This study investigated the use of 18F-2-fluoro-2-deoxy-D-glucose positron emission tomography (18F-FDG-PET) to follow-up during treatment and predict the outcomes of patients with high-risk localized rectal cancer. Researchers suggested that this method can be very useful to assess the tumor before the surgery and predict response to...Read More
In a nutshell This phase 3 trial is examining the effectiveness and safety of low dose rate (LDR) vs high dose rate (HDR) prostate brachytherapy (BT) for patients with prostate cancer (PC). The main outcome to be measured will be the quality of life in terms of urinary symptoms. This trial is recruiting in British Columbia,...Read More
In a nutshell This study evaluated whether treating breast cancer that has not been completely removed with more surgery was more effective than non-surgical options such as chemotherapy. This study found that there was no difference in outcomes between treating with further surgery versus treating with a non-surgical option. Some...Read More
In a nutshell This study compared the safety of two different doses of nivolumab (Opdivo) plus ipilimumab (Yervoy) for patients with advanced melanoma. This study concluded that patients treated with nivolumab at 3mg/kg and ipilimumab at 1mg/kg had fewer side effects. Some background Advanced melanoma can be difficult to treat....Read More
Is vascular-targeted photodynamic therapy or active surveillance more effective in the treatment of low-risk prostate cancer?
In a nutshell This study examined if vascular-targeted photodynamic therapy (VTPT), or active surveillance is more effective in the treatment of low-risk prostate cancer. This study concluded that patients who received VTPT were less likely to require radical therapy compared to those who underwent active surveillance. Some background...Read More
In a nutshell This study examined the safety and effectiveness of slow-release leuprolide mesylate (LM) administered by injection under the skin (leuprolide mesylate subcutaneous injectable suspension or LMIS), in the treatment of advanced prostate cancer. This study concluded that this medication is safe and effective in the treatment of advanced...Read More
In a nutshell This study determined whether osimertinib (Tagrisso) was more effective than erlotinib (Tarceva) in patients with non-small cell lung cancer (NSCLC) with the EGFR mutation. The study found that treatment with osimertinib improved survival compared to standard-care treatment for these patients. Some background...Read More
In a nutshell This phase 2 trial will investigate the safety and effectiveness of a new targeted therapy drug, INCMGA00012 in metastatic (spread to other organs) non-small cell lung cancer (NSCLC). The main outcome will be the overall response rate. This trial is recruiting in Texas, United States. The details NSCLC is the most common form of...Read More